

**Draft Guidance for Industry**  
**Minimally Manipulated, Unrelated, Allogeneic Placental/Umbilical**  
**Cord Blood Intended or Hematopoietic Reconstitution in**  
**Patients with Hematological Malignancies**

**December 2006**

**(Docket No. 2006D-0514)**

**REFERENCES**

1. Food and Drug Administration, Center for Biologics Evaluation and Research, Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products, November 1994 (<http://www.fda.gov/cder/guidance/cmc2.pdf>).
2. Guidance for Industry: Q7A Good Manufacturing Practice Guidance for Active Pharmaceuticals Ingredients, August 2001 (<http://www.fda.gov/cber/gdlns/ichactive.pdf>).
3. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, September 2004 (<http://www.fda.gov/cber/gdlns/steraseptic.pdf>).

**OTHER**

Summary Minutes, Biological Response Modifiers Advisory Committee, Meeting #34, February 27, 2003, Silver Spring, Maryland  
(<http://www.fda.gov/ohrms/dockets/ac/03/minutes/3924M2.htm> )